Patents by Inventor Eric Pamer
Eric Pamer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11860163Abstract: The present invention relates to compositions, methods, and kits for predicting a subject's response to a CAR T cell therapy, by analyzing the intestinal microbiome of the subject. The present disclosure also provides a method of detecting patients at risk for a poor response to CAR T cell therapy by measuring the level of the presently disclosed bacteria or bacterial genes in the microflora or microbiome of a patient receiving or considered for CAR T cell therapy. The present disclosure further provides therapeutic compositions and methods for treating a subject having a cancer, by improving the subject's response to a CAR T cell therapy.Type: GrantFiled: April 13, 2021Date of Patent: January 2, 2024Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Melody Smith, Marcel van den Brink, Eric Pamer, Eric Littmann
-
Publication number: 20230190825Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.Type: ApplicationFiled: October 17, 2022Publication date: June 22, 2023Applicant: Memorial Sloan-Kettering Cancer CenterInventors: Eric Pamer, Charlie Buffie, Peter McKenney
-
LANTIBIOTICS, LANTIBIOTIC-PRODUCING BACTERIA, COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF
Publication number: 20220370547Abstract: The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.Type: ApplicationFiled: December 28, 2021Publication date: November 24, 2022Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Eric Pamer, Sohn Kim, Peter McKenney, Silvia Caballero -
Patent number: 11471495Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.Type: GrantFiled: July 26, 2019Date of Patent: October 18, 2022Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Eric Pamer, Charlie Buffie, Peter McKenney
-
Patent number: 11364269Abstract: The disclosure relates to a therapeutic composition for treating L. monocytogenes infection or L. monocytogenes colonization, the composition including at least one, at least two, at least three, or all of an isolated C. saccharogumia bacteria, an isolated C. ramosum bacteria, an isolated C. hathewayi bacteria, and/or an isolated B. producta bacteria in a formulation suitable for administration to a subject. The disclosure further provides similar compositions lacking an isolated C. saccharogumia bacteria. The disclosure additionally provides methods of treating L. monocytogenes infection or colonization using such compositions.Type: GrantFiled: November 19, 2019Date of Patent: June 21, 2022Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Simone Becattini, Eric Pamer, Sohn Kim
-
Publication number: 20220096567Abstract: The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.Type: ApplicationFiled: December 13, 2021Publication date: March 31, 2022Applicant: Memorial Sloan Kettering Cancer CenterInventors: Eric Pamer, Peter McKenney, Silvia Caballero
-
Lantibiotics, lantibiotic-producing bacteria, compositions and methods of production and use thereof
Patent number: 11207374Abstract: The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.Type: GrantFiled: October 21, 2019Date of Patent: December 28, 2021Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Eric Pamer, Sohn Kim, Peter McKenney, Silvia Caballero -
Patent number: 11197897Abstract: The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.Type: GrantFiled: May 8, 2020Date of Patent: December 14, 2021Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Eric Pamer, Peter McKenney, Silvia Caballero
-
Publication number: 20210369795Abstract: The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.Type: ApplicationFiled: June 17, 2021Publication date: December 2, 2021Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Eric Pamer, Jedd D. Wolchok, Krista Dubin
-
Publication number: 20210231657Abstract: The present invention relates to compositions, methods, and kits for predicting a subject's response to a CAR T cell therapy, by analyzing the intestinal microbiome of the subject. The present disclosure also provides a method of detecting patients at risk for a poor response to CAR T cell therapy by measuring the level of the presently disclosed bacteria or bacterial genes in the microflora or microbiome of a patient receiving or considered for CAR T cell therapy. The present disclosure further provides therapeutic compositions and methods for treating a subject having a cancer, by improving the subject's response to a CAR T cell therapy.Type: ApplicationFiled: April 13, 2021Publication date: July 29, 2021Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Melody Smith, Marcel van den Brink, Eric Pamer, Eric Littmann
-
Patent number: 11045506Abstract: The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.Type: GrantFiled: May 21, 2018Date of Patent: June 29, 2021Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Eric Pamer, Jedd D. Wolchok, Krista Dubin
-
Publication number: 20210000887Abstract: The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.Type: ApplicationFiled: May 8, 2020Publication date: January 7, 2021Applicant: Memorial Sloan Kettering Cancer CenterInventors: Eric Pamer, Peter McKenney, Silvia Caballero
-
Patent number: 10646520Abstract: The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.Type: GrantFiled: May 22, 2018Date of Patent: May 12, 2020Assignee: Memorial Sloan Kettering Cancer CenterInventors: Eric Pamer, Peter McKenney, Silvia Caballero
-
LANTIBIOTICS, LANTIBIOTIC-PRODUCING BACTERIA, COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF
Publication number: 20200093886Abstract: The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.Type: ApplicationFiled: October 21, 2019Publication date: March 26, 2020Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: ERIC PAMER, SOHN KIM, PETER MCKENNEY, SILVIA CABALLERO -
Publication number: 20200085886Abstract: The disclosure relates to a therapeutic composition for treating L. monocytogenese infection or L. monocytogenese colonization, the composition including at least one, at least two, at least three, or all of an isolated C. saccharogumia bacteria, an isolated C. ramosum bacteria, an isolated C. hathewayi bacteria, and/or an isolated B. producta bacteria in a formulation suitable for administration to a subject. The disclosure further provides similar compositions lacking an isolated C. saccharogumia bacteria. The disclosure additionally provides methods of treating L. monocytogenes infection or colonization using such compositions.Type: ApplicationFiled: November 19, 2019Publication date: March 19, 2020Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Simone Becattini, Eric Pamer, Sohn Kim
-
Publication number: 20190381113Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.Type: ApplicationFiled: July 26, 2019Publication date: December 19, 2019Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Eric Pamer, Charlie Buffie, Peter McKenney
-
Publication number: 20180360892Abstract: The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.Type: ApplicationFiled: May 21, 2018Publication date: December 20, 2018Inventors: Eric Pamer, Jedd D. Wolchok, Krista Dubin
-
Publication number: 20180256653Abstract: The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.Type: ApplicationFiled: May 22, 2018Publication date: September 13, 2018Inventors: Eric Pamer, Peter McKenney, Silvia Caballero
-
Publication number: 20170087196Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.Type: ApplicationFiled: May 19, 2015Publication date: March 30, 2017Inventors: Eric Pamer, Charlie Buffie, Peter McKenney